Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00140309 · ClinicalTrials.gov registry record · Phase 2
TBTC Study 27: Moxifloxacin vs Ethambutol for TB Treatment
A Phase 2 study, sponsored by Centers for Disease Control and Prevention.
- Completed
- Registry status
- Phase 2
- Development phase
- 350
- Enrollment target
NCT00140309 is a Phase 2 study that has completed, run by Centers for Disease Control and Prevention. The registered enrollment target is 350 participants.
The verdict
NCT00140309, a Phase 2 study, has completed, sponsored by Centers for Disease Control and Prevention.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 350 participants
- Enrollment target
Study Summary
This study is a placebo-controlled factorial study, randomized to study drug (moxifloxacin vs. ethambutol) and treatment frequency (daily vs. thrice weekly after an initial two weeks of daily therapy) during the first two months of standard treatment (with isoniazid, rifampin, and pyrazinamide) for sputum smear-positive pulmonary tuberculosis.
Interventions
- DRUG moxifloxacin (with isoniazid, rifampin, pyrazinamide)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2003-07 |
| Est. Completion | 2005-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00140309
The ClinicalTrials.gov registry entry for NCT00140309 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Centers for Disease Control and Prevention, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which moxifloxacin (with isoniazid, rifampin, pyrazinamide) is the first listed.
NCT00140309 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00140309 about?
NCT00140309 is a clinical study titled "TBTC Study 27: Moxifloxacin vs Ethambutol for TB Treatment". This study is a placebo-controlled factorial study, randomized to study drug (moxifloxacin vs. ethambutol) and treatment frequency (daily vs. thrice weekly after an initial two weeks of daily therapy) during the first two months of standard treatment (with isoniazid, rifampin, and pyrazinamide) for ...
What is the current status of trial NCT00140309?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 350 participants. The study started on 2003-07. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00140309?
The interventions under investigation include: moxifloxacin (with isoniazid, rifampin, pyrazinamide) (DRUG).
Who is sponsoring clinical trial NCT00140309?
This trial is sponsored by Centers for Disease Control and Prevention, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.